These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 29887601)
1. Ivacaftor CFTR Potentiator Therapy is Efficient for Pancreatic Manifestations in Cystic Fibrosis. Kounis I; Lévy P; Rebours V Am J Gastroenterol; 2018 Jul; 113(7):1058-1059. PubMed ID: 29887601 [No Abstract] [Full Text] [Related]
2. The effect of CFTR modulators on a cystic fibrosis patient presenting with recurrent pancreatitis in the absence of respiratory symptoms: a case report. Johns JD; Rowe SM BMC Gastroenterol; 2019 Jul; 19(1):123. PubMed ID: 31296159 [TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies. McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001 [TBL] [Abstract][Full Text] [Related]
4. Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians. Casciaro R; Costa S; Dang P; Majo F; Ros M Clin Respir J; 2018 Apr; 12(4):1767-1768. PubMed ID: 28759146 [No Abstract] [Full Text] [Related]
5. Ivacaftor for patients with cystic fibrosis. Wainwright CE Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205 [TBL] [Abstract][Full Text] [Related]
6. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis. Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948 [TBL] [Abstract][Full Text] [Related]
7. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. McPhail GL; Clancy JP Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952 [TBL] [Abstract][Full Text] [Related]
8. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis. Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688 [No Abstract] [Full Text] [Related]
9. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Kuk K; Taylor-Cousar JL Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827 [TBL] [Abstract][Full Text] [Related]
10. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
11. The evidence for long-term benefits of restoration of CFTR function continues to grow. Boyle MP Am J Respir Crit Care Med; 2015 Oct; 192(7):774-6. PubMed ID: 26426780 [No Abstract] [Full Text] [Related]
18. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. Rehman A; Baloch NU; Janahi IA N Engl J Med; 2015 Oct; 373(18):1783. PubMed ID: 26510035 [No Abstract] [Full Text] [Related]
19. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. Wainwright CE; Elborn JS; Ramsey BW N Engl J Med; 2015 Oct; 373(18):1783-4. PubMed ID: 26510034 [No Abstract] [Full Text] [Related]
20. Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor. Munce D; Lim M; Akong K Pediatr Pulmonol; 2020 Dec; 55(12):3381-3383. PubMed ID: 32910556 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]